Novo Nordisk A/S

New York Stock Exchange
Back to all articles
Slightly Bearish -20

Novo Nordisk (CPH:NOVO-B) rises, but volume stays light ahead of August ...

📉 Novo Nordisk shares closed Friday at DKK 326.90, dropping 1.54% but remaining up 2.8% for the week, lagging the OMX Copenhagen 25 benchmark by 2.6 percentage points.

📊 Trading volume was light with Friday turnover hitting 2.58 million shares (45% of average) and weekly total down to 19.23 million from 25.66 million a week prior.

🗓️ The company is scheduled to report first-half results on August 5 at 07:30 CEST, with investors awaiting clarity on the GLP-1 profit bridge.

📉 In May, Novo Nordisk lowered its 2026 outlook for adjusted sales and operating profit, now guiding for a 4% to 12% drop at constant exchange rates.

💰 First-quarter adjusted net sales fell 4% to DKK 70.06 billion while adjusted operating profit slipped 6% to DKK 32.86 billion.

🧬 Novo Nordisk will present new haemophilia data from the FRONTIER4 study and explorer10 results at the ISTH Congress in Paris from July 11-15.

💊 CEO Mike Doustdar stated that Wegovy is driving a strong start to 2026, specifically citing increased uptake of the new pill formulation.

🇺🇸 The ADR closed at $50.43 in New York on July 2, trading independently from Copenhagen due to the NYSE closure for Independence Day.

⚠️ CFO Karsten Munk Knudsen described predicting when market conditions might turn as really hard amidst compounding market unpredictability.

📈 Portfolio manager Markus Manns noted that nobody had a double-digit profit decline on the agenda prior to the recent guidance cuts.

Bullish Signals
  • Novo Nordisk shares are up 2.8% for the week despite lagging the broader Danish market, indicating underlying buyer support.
  • CEO Mike Doustdar confirmed that Wegovy is driving a strong start to 2026 with specific uptake of the new pill formulation.
  • The company has significant upcoming data presentations at the ISTH Congress in Paris regarding its haemophilia pipeline assets denecimig and concizumab.
Risk Factors
  • Novo Nordisk lowered its 2026 outlook for adjusted sales and operating profit, now guiding for a 4% to 12% drop at constant exchange rates.
  • First-quarter adjusted net sales dropped 4% to DKK 70.06 billion and adjusted operating profit slipped 6% to DKK 32.86 billion.
  • The company cites unprecedented pricing pressure in the U.S., more competition, and expiring semaglutide patents outside the region as drivers for the decline.
  • Trading volume remained light at 45% of the 65-day average on Friday, suggesting a lack of significant long-only fund participation ahead of August results.
  • CFO Karsten Munk Knudsen warned that predicting if and when the tide turns in the market is really hard.
Full Analysis
Novo Nordisk (NVO) shares finished the week with a modest rally, closing Friday at DKK 326.90 despite a 1.54% daily drop, resulting in a 2.8% weekly gain that lagged the OMX Copenhagen 25 benchmark by 2.6 percentage points. Trading volume remained thin, hitting 2.58 million shares on Friday (45% of the 65-day average) and totaling 19.23 million for the week, down from the previous week's 25.66 million. The lighter tape allowed buyers to push prices higher without significant new GLP-1 updates driving the move. The company faces a critical pivot point as it prepares to report first-half results on August 5 at 07:30 CEST. In May, Novo Nordisk revised its 2026 outlook downward, projecting a 4% to 12% drop in adjusted sales and operating profit at constant exchange rates, citing unprecedented pricing pressure in the U.S., increased competition, and expiring semaglutide patents outside the region. First-quarter data confirmed these headwinds, with adjusted net sales dropping 4% to DKK 70.06 billion and adjusted operating profit slipping 6% to DKK 32.86 billion. Beyond weight-loss drugs, Novo Nordisk is advancing its haemophilia portfolio with new results from the FRONTIER4 study of denecimig and explorer10 for concizumab set for presentation at the ISTH Congress in Paris from July 11-15. CEO Mike Doustdar highlighted that Wegovy is driving a strong start to 2026, specifically noting uptake of the new pill formulation. However, analysts remain cautious about whether long-only funds are returning ahead of the August earnings release given the lack of fresh positive catalysts during the week. Market attention now focuses on whether the ADR price in New York will slip to match Copenhagen's performance or if U.S. healthcare flows sustain its rebound following Independence Day. CFO Karsten Munk Knudsen noted the difficulty in predicting when market conditions might turn, while portfolio manager Markus Manns remarked that a double-digit profit decline was not previously on anyone's agenda. Investors are weighing the potential for a bounce against the structural challenges of pricing pressure and patent cliffs.